Envision Ocular, LLC

Running trials

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

  NCT07496567· Phase 2/3· Source

• Recruiting

  Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT07064759· Phase 3· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· Source

• Active, not recruiting

  A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

  NCT06722157· Phase 2· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

  NCT06495918· Phase 3· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Source

• Active, not recruiting

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

  NCT06116916· Phase 2· Source

• Active, not recruiting

  Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

  NCT05387837· Phase 2· Source

• Active, not recruiting

  A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Phase 4· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

  NCT04108156· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting
• Diabetic eye disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

  NCT06270836· Phase 3· Source

• Completed

  Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

  NCT05891548· Phase 2· Source

• Completed

  A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

  NCT05230537· Phase 2· Source

• Completed

  Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

  NCT04567303· Phase 1/2· Source

• Completed

  A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Phase 3· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source